Immunotherapies are used to treat a portion of patients for almost every type of cancer. Some immunotherapies only work for a select group of people whose tumors express certain features. Tumor tests can help determine which patients are more or less likely to benefit from these therapies.

The choice of immunotherapies vary by cancer type, and situation. Many of the available immunotherapies are used for advanced or cancers. Visit the Cancer Treatment by Cancer Type section for more information on immunotherapies for a specific type of cancer.

The following are common immunotherapies. This is not a complete list of all immunotherapies or indications. Speak with your doctor about other treatments which may be available.

Immune checkpoint inhibitors
Monoclonal antibodies
Nonspecific immunotherapies
Cancer vaccines

Immune checkpoint inhibitors

	Cancer type	Indication
Keytruda (pembrolizumab)	or unresectable	For treatment of that have progressed after treatment and for which there are no other treatment options	High (MSI-H) or ()
	or unresectable	For the treatment of that have progressed following prior treatment and who have no satisfactory alternative treatment options	High (TMB-H)
	Triple-Negative Breast Cancer	Combined with chemotherapy for treatment of locally recurrent unresectable or triple negative breast cancer	and PD-L1-positive
	or unresectable colorectal cancer	For first-line treatment of or unresectable colorectal cancer	High (MSI-H) or ()
	or unresectable colorectal cancer	Cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan	High (MSI-H) or ()
	Advanced endometrial cancer	Combined with Lenvima (lenvatinib) for patients whose cancer has progressed after prior therapy and who are not candidatesfor surgery or radiation	Negative for () or negative for ()
	or unresectable melanoma	For the treatment of patients with melanoma	No required
	Melanoma	For the treatment of patients with involvement of lymph node(s) following complete resection	No required
Opdivo (nivolumab)	colorectal cancer	As a single agent or in combination with Yervoy (ipilimumab) for cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan	High (MSI-H) or ()
	or unresectable melanoma	As a single agent or combined with ipilimumab	No required
	or lymph node positive melanoma	For the treatment of patients following complete resection	No required
Tecentriq (atezolizumab)	breast cancer	Combined with Abraxane (protein-bound paclitaxel)	Triple-negative ( and ) PD-L1-positive
Yervoy (ipilumumab)	colorectal cancer	Combined with Opdivo (nivolumab) for cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan	High (MSI-H) or ()
	or unresectable melanoma	For the treatment of patients with melanoma	No required
	Melanoma	treatment of patients with cutaneous melanoma with pathologic involvement of regional of more than 1 mm who have undergone complete resection, including total lymphadenectomy	No required

Monoclonal antibiodies

	Cancer type	Indication		Type of agent
Avastin (bevacizumab)	2-4 ovarian, fallopian tube or primary peritoneal cancer	Combined with Lynparza (olaparib) for first-line, for platinum-sensitive cancer	Deficiency () testing	Monoclonal antibody targeting vascular endothelial growth factor (VEGF)
	3-4 ovarian, or primary peritoneal cancer	Combined with chemotherapy, followed by Avastin as a single agent following initial surgical resection	No required	Monoclonal antibody targeting vascular endothelial growth factor (VEGF)
	Recurrent ovarian, or primary peritoneal cancer	Combined with chemotherapy for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens	No required	Monoclonal antibody targeting vascular endothelial growth factor (VEGF)
	Recurrent ovarian, or primary peritoneal cancer	Combined with chemotherapy, followed by Avastin as a single agent, for platinum-sensitive recurrent diesase	No required	Monoclonal antibody targeting vascular endothelial growth factor (VEGF)
	colorectal cancer	Combined with intravenous 5-fluorouracil-based chemotherapy for first- or second-line treatment	No required	Monoclonal antibody targeting vascular endothelial growth factor (VEGF)
	colorectal cancer	In combination with chemotherapy for second-line treatment in patients who have progressed on a first-line Avastin-containing regimen	No required	Monoclonal antibody targeting vascular endothelial growth factor (VEGF)
Cyramza (ramucirumab)	colorectal cancer	Combined with FOLFIRI chemotherapy, for treatment after disease progression on, or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine	No required	Monoclonal antibody targeting vascular endothelial growth factor (VEGF)
Erbitux (cetuximab)	colorectal cancer	Combined with FOLFIRI for first-line treatment, or combined with irinotecan for cancers that no longer respond to irinotecan-based chemotherapy or as a single agent in patients who have progressed after oxaliplatin- and irinotecan-based chemotherapy	EGFR positive and KRAS mutation negative	Monoclonal antibody targeting epidermal growth factor receptor (EGFR)
Herceptin (trastuzumab)	Breast cancer	The treatment of breast cancer	overexpression ()	Antibody targeting receptors
Kadcyla (trastuzumab emtansine)	Breast cancer	treatment of patients with early breast cancer who have residual invasive disease after taxane and trastuzumab-based treatment	overexpression ()	Antibody-drug conjugate targeting receptors
Perjeta (pertuzumab)	Breast cancer	Combined with Herceptin (trastuzumab) and docetaxel as treatment of patients with , locally advanced, inflammatory, or early breast cancer	overexpression ()	Antibody targeting receptors
Phesgo (pertuzumab, trastuzumab combined injection)	Breast cancer	Prior to surgery ( treatment) when the tumor is greater than 2 cm in diameter or node-positive or after surgery ( treatment) for early breast cancer that has a high likelihood of coming back	overexpression ()	Antibody targeting receptors
Trodelvy (sacituzumab govitecan-hziy)	breast cancer	For breast cancer that progressed, recurred or did not respond to at least two previous lines of treatment	Triple-negative (, )	Antibody-drug conjugate (chemotherapy attached to antibody found in )
Vectibix (panitumumab)	colorectal cancer	Combined with FOLFOX for first-line treatment	Negative for KRAS and NRAS tumor mutation	Monoclonal antibody targeting epidermal growth factor receptor (EGFR)
Vectibix (panitumumab)	colorectal cancer	As a single therapy following disease progression after prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy	Negative for KRAS and NRAS tumor mutations	Monoclonal antibody targeting epidermal growth factor receptor (EGFR)

Nonspecific immunotherapies

	Cancer type	Indication
Proleukin® (aldesleukin)	melanoma	For the treatment of patients with melanoma
Intron A	Melanoma	As to surgical treatment in patients 18 years of age or older with melanoma who are free of disease but at high risk for systemic recurrence, within 56 days of surgery
Sylatron	Melanoma	As treatment of melanoma with nodal involvement within 84 days of surgery

Cancer vaccines

	Cancer type	Indication
Provenge (sipuleucel-T)	castration resistant cancer (mCRPC)	For the treatment of asymptomatic or minimally symptomatic castrate resistant cancer	No required
Imlygic (T-VEC or talimogene laherparepvec)	Unresectable recurrent melanoma	For local treatment of cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery	No required